title: XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
abstract: The fact that intron single nucleotide polymorphisms could regulate gene expression or even alter gene expression levels has been the focus of attention. To study the relationship between the intron 11 C/A single nucleotide polymorphism of XPC gene and the efficacy of vinorelbine and cisplatin (NP) chemotherapy, 164 patients with non-small cell lung cancer (NSCLC) taking NP chemotherapy drugs were evaluated according to the efficacy of the treatment. We used polymerase chain reaction restriction fragment length polymorphism to examine the C/A polymorphism in the XPC gene intron 11 of the DNA samples extracted from peripheral blood. It was found that the frequency of patients in the effective group with C/C+C/A genotype (37.6%) had significant difference to chemotherapy than that of patients with A/A homozygotes (27.7%) in the same group (P=0.043, odds ratio=2.366, 95% confidence interval=1.026-5.457). Therefore, NSCLC patients with the C/C+C/A genotype are more sensitive to NP treatment than those with the A/A genotype. The XPC gene intron 11 C/A polymorphism may be a predictive biomarker for sensitivity to NP chemotherapy in patients with NSCLC.
authors.affiliation: Cancer Control Laboratory of Cancer Institute and General Surgery, First Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Li-Bo
authors.initials: LB
authors.lastname: Zhu
authors.forename: Qian
authors.initials: Q
authors.lastname: Xu
authors.forename: Cheng-Yu
authors.initials: CY
authors.lastname: Hong
authors.forename: Zheng
authors.initials: Z
authors.lastname: Yue
authors.forename: Ye
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hui-Nan
authors.initials: HN
authors.lastname: Ye
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D002945:Cisplatin / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000097:blood / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005819:Genetic Markers; D006801:Humans; D007438:Introns; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D004268:DNA-Binding Proteins; D005819:Genetic Markers; C086984:XPC protein, human; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine